ALXO Q4 2024 Earnings — ALX Oncology Holdings Inc. Revenue & Financial Results | Market Cap Arena

ALXOALX Oncology Holdings Inc.

$112M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$31M

Net Income

-$29M

EPS (Diluted)

$-0.55

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$32M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$148M

Total Liabilities

$34M

Stockholders' Equity

$114M

Cash & Equivalents

$18M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$31M	-$48M	+36.3%
Net Income	-$29M	-$45M	+35.9%